Evidence map›Paper›PMID 32762272›Full record

ArticleJournal of psychopharmacology (Oxford, England)2020

The effects of acute cannabidiol on cerebral blood flow and its relationship to memory: An arterial spin labelling magnetic resonance imaging study.

Michael A P Bloomfield, Sebastian F Green, Chandni Hindocha, Yumeya Yamamori, Jocelyn Lok Ling Yim, Augustus P M Jones, Hannah R Walker, Pawel Tokarczuk, Ben Statton, Oliver D Howes and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of psychopharmacology (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it, 37 citations in OpenAlex.

  1. Does acute cannabidiol (CBD) use impair performance? A meta-analysis and comparison with placebo and delta-9-tetrahydrocannabinol (THC).Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Acute effects of ΔPsychopharmacology · 2022
    Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Michael A P BloomfieldTranslational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.ORCID 0000-0002-1972-4610
Sebastian F GreenTranslational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.
Chandni HindochaTranslational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.ORCID 0000-0003-1692-7401
Yumeya YamamoriTranslational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.
Jocelyn Lok Ling YimTranslational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.
Augustus P M JonesTranslational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.
Hannah R WalkerTranslational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.
Pawel TokarczukMedical Research Council London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.
Ben StattonMedical Research Council London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.
Oliver D HowesPsychiatric Imaging Group, Medical Research Council London Institute of Medical Sciences, Imperial College London, Hammersmith Hospital, London, UK.
H Valerie CurranClinical Psychopharmacology Unit, Research Department of Clinical, Educational and Health Psychology, University College London, London, UK.
Tom P FreemanTranslational Psychiatry Research Group, Research Department of Mental Health Neuroscience, Division of Psychiatry, Institute of Mental Health, University College London, London, UK.
Mental Health Research UK · GBUniversity College Hospital · GBHammersmith Hospital · GBKing's College London · GB

Funding

Medical Research Council MC_U120097115
6 · The paper itself

Abstract

backgroundCannabidiol (CBD) is being investigated as a potential treatment for several medical indications, many of which are characterised by altered memory processing. However, the mechanisms underlying these effects are unclear.

aimsOur primary aim was to investigate how CBD influences cerebral blood flow (CBF) in regions involved in memory processing. Our secondary aim was to determine if the effects of CBD on CBF were associated with differences in working and episodic memory task performance.

methodsWe used a randomised, crossover, double-blind design in which 15 healthy participants were administered 600 mg oral CBD or placebo on separate days. We measured regional CBF at rest using arterial spin labelling 3 h after drug ingestion. We assessed working memory with the digit span (forward, backward) and n-back (0-back, 1-back, 2-back) tasks, and we used a prose recall task (immediate and delayed) to assess episodic memory.

resultsCBD increased CBF in the hippocampus (mean (95% confidence intervals) = 15.00 (5.78-24.21) mL/100 g/min,

conclusionsThese findings suggest that CBD increases CBF to key regions involved in memory processing, particularly the hippocampus. These results identify potential mechanisms of CBD for a range of conditions associated with altered memory processing, including Alzheimer's disease, schizophrenia, post-traumatic stress disorder and cannabis-use disorders.

Indexed as

Memory, EpisodicAdultCannabidiolCannabinoid Receptor ModulatorsCerebrovascular CirculationFemaleHippocampusHumansMagnetic Resonance ImagingMaleMemory, Short-TermMental RecallPrefrontal CortexPsychomotor PerformanceSpin LabelsYoung AdultCannabidiolCannabinoid Receptor ModulatorsSpin LabelsASLcannabidiolhippocampusmemoryMRIperfusion

Identifiers

PMID32762272
PMCPMC7436497
OpenAlexW3047624740

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.